Notably, mice rechallenged with tumors on the contralateral side remained tumor-free for over 6 months, underscoring the therapeutic potential of EphA3-directed immunotherapy (Lertsumitkul et al., 2024). This evidence concerns the gene EPHA3 and neoplasm.